122 related articles for article (PubMed ID: 10213463)
1. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy.
Antonelli G; Simeoni E; Turriziani O; Tesoro R; Redaelli A; Roffi L; Antonelli L; Pistello M; Dianzani F
J Interferon Cytokine Res; 1999 Mar; 19(3):243-51. PubMed ID: 10213463
[TBL] [Abstract][Full Text] [Related]
2. MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha.
Meier V; Mihm S; Ramadori G
J Med Virol; 2000 Nov; 62(3):318-26. PubMed ID: 11055241
[TBL] [Abstract][Full Text] [Related]
3. MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment.
Kong XF; Zhang XX; Gong QM; Gao J; Zhang SY; Wang L; Xu J; Han Y; Jin GD; Jiang JH; Zhang DH; Lu ZM
J Interferon Cytokine Res; 2007 Sep; 27(9):809-18. PubMed ID: 17892402
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C.
Massirer KB; Hirata MH; Silva AE; Ferraz ML; Nguyen NY; Hirata RD
Braz J Med Biol Res; 2004 May; 37(5):643-7. PubMed ID: 15107924
[TBL] [Abstract][Full Text] [Related]
5. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients.
Shaker O; Ahmed A; Doss W; Abdel-Hamid M
J Viral Hepat; 2010 Nov; 17(11):794-9. PubMed ID: 20002306
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus.
Fernández M; Quiroga JA; Martín J; Herrero M; Pardo M; Horisberger MA; Carreño V
J Infect Dis; 1999 Aug; 180(2):262-7. PubMed ID: 10395838
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
Meier V; Mihm S; Ramadori G
J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
[TBL] [Abstract][Full Text] [Related]
8. Differential transcriptional expresión of the polymorphic myxovirus resistance protein A in response to interferon-alpha treatment.
Fernández-Arcás N; Blanco A; Gaitán MJ; Nyqvist M; Alonso A; Reyes-Engel A
Pharmacogenetics; 2004 Mar; 14(3):189-93. PubMed ID: 15167707
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers for response to interferon therapy?
Bezares F; Kohan S; Sacerdote de Lustig E; Farías E; Murro H; Horisberger MA
J Interferon Cytokine Res; 1996 Jul; 16(7):501-5. PubMed ID: 8836914
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphisms of MxA protein and eIF-2a-reg2 and their responses to interferon treatment in patients with chronic hepatitis B].
Huang YX; Ma LN; Chen XY; Li Z; Huang YL; Shen CL; Ma B
Zhonghua Gan Zang Bing Za Zhi; 2007 Mar; 15(3):187-91. PubMed ID: 17407708
[TBL] [Abstract][Full Text] [Related]
11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
Hsi E; Huang CF; Dai CY; Juo SH; Chou WW; Huang JF; Yeh ML; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML
Antiviral Res; 2014 May; 105():135-42. PubMed ID: 24637254
[TBL] [Abstract][Full Text] [Related]
14. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells.
Ronni T; Sareneva T; Pirhonen J; Julkunen I
J Immunol; 1995 Mar; 154(6):2764-74. PubMed ID: 7876547
[TBL] [Abstract][Full Text] [Related]
15. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon.
Hijikata M; Ohta Y; Mishiro S
Intervirology; 2000; 43(2):124-7. PubMed ID: 10971132
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.
Gilli F; Sala A; Bancone C; Salacone P; Gallo M; Gaia E; Bertolotto A
J Immunol Methods; 2002 Apr; 262(1-2):187-90. PubMed ID: 11983232
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.
MacQuillan GC; de Boer WB; Platten MA; McCaul KA; Reed WD; Jeffrey GP; Allan JE
J Med Virol; 2002 Oct; 68(2):197-205. PubMed ID: 12210408
[TBL] [Abstract][Full Text] [Related]
18. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study.
Fujiwara D; Hino K; Yamaguchi Y; Kubo Y; Yamashita S; Uchida K; Konishi T; Nakamura H; Korenaga M; Okuda M; Okita K
J Viral Hepat; 2004 Mar; 11(2):136-40. PubMed ID: 14996348
[TBL] [Abstract][Full Text] [Related]
19. The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene.
Ronni T; Matikainen S; Lehtonen A; Palvimo J; Dellis J; Van Eylen F; Goetschy JF; Horisberger M; Content J; Julkunen I
J Interferon Cytokine Res; 1998 Sep; 18(9):773-81. PubMed ID: 9781817
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
